[Toronto, March 6, 2024] – The AACR Annual Meeting is one of the most significant gatherings in the field of oncology, attracting leading scientists, clinicians, and industry professionals worldwide. This year’s AACR 2024, taking place from April 5th to 10th in San Diego, provides a platform for Geneseeq to showcase its latest advancements in cancer genomics and personalized medicine

Geneseeq’s mini-oral presentations will release the most recent results from multi-cancer early detection(MCED) case-control study and the “Jinling cohort,” a 15,000-participant perspective MCED cohort study. In addition to the mini-oral presentations, Geneseeq will present ten posters featuring a diverse range of studies covering various aspects of minimal residual disease (MRD), cancer genomics and biomarker identification.

 

 

Format Poster ID Title

Mini Oral

1266

Development And Performance of A Multi-Cancer Early Detection Test Utilizing Plasma cfDNA Fragmentomics: A Large-Scale, Prospective, Multicenter Study

Mini Oral

1263

Interim Results From a Large-Scale, Prospective Cohort Study (JINLING) for Multi-Cancer Early Detection Test in Average-Risk Asymptomatic Patients

Poster

6093 / 19

Evaluation of Preanalytical and Physiological Variables Affecting cfDNA-Based Multi-Cancer Early Detection Test

Poster

5047 / 1

Identifying Genomic Features Associated with Pathologic Lymph Node Metastasis in Lung Adenocarcinoma Patients

Poster

6466 / 13

Multi-omics Analysis of Molecular Characteristics and Transformation Mechanisms of Stage I-III Micropapillary Lung Adenocarcinoma

Poster

5132 / 5

Multi-Omics Analysis Uncovers Predictive Biomarkers for the Efficacy and Outcomes of Immune Checkpoint Inhibitor in Combination with Chemotherapy Inadvanced Unresectable Biliary Tract Cancers

Poster

7408 / 3

Robust Profiling of Cancer-Related Gene Fusions: Analytical Validation of PANCARNA for Multiple Cancer Types

Poster

3685 / 30

Improved Detection of Minimal Residual Disease in Colorectal Cancer Patients Using Adaptive Noise Cancellation Algorithm

Poster

3684 / 29

Comprehensive Error Suppressing Approach Allowing Enhanced Minimal Residual Disease Detection in Lung Cancer Patients

Poster

5208 / 16 

Dynamic Changes in Circulating Tumor DNA and T Cell Receptor Repertoire Predict Disease Progression in Patients with Unresectable Esophageal Squamous Cell Carcinoma

Poster

2528 / 16

Genomic and Immune Microenvironment Features Influencing Chemoimmunotherapy Response in Gastric Cancer with Peritoneal Metastasis: A Retrospective Cohort Study

Poster

6412 / 24

Combination of Liquid Biopsy and PET/CT Enhances Prediction of Pathological Response to Neoadjuvant Immunochemotherapy in Patients with Esophageal Squamous Cell Carcinoma